 |
|
 |
Drug Discovery |
|
|
Impact of Nanotechnology in Drug Discovery; The
Publication Date March 2005
Publisher NanoMarkets
Product Type Report
Pages 200
ISBN Number not applicable
Product Code NAN002
|
|
|
Summary
The pharmaceutical industry is facing challenges on many fronts:
• Neither big pharma nor the biotech industry is as able to come up with blockbuster drugs as in the past.
• There are increasing pressures to reduce R&D costs.
• There is a need to put more chemical entities in the R&D drug pipeline and do so faster.
• There is also a need to decrease time to market. Each day delayed in development time can correspond to between $1 million-$3 million in lost revenue and it can take an estimated 7-10 years to develop and market a drug at costs measured in the hundreds of millions of dollars
• The human genome project is expected to lead to approximately 100,000 targets (points of intervention) that will require evaluation against many compound libraries in the hopes of creating new drug opportunities.
• The efforts expended in extending patent protections is a defensive strategy that may protect vital revenue streams but does little to ensure longer-term success.
Nanotechnology can and will resolve some of the pharma and biotech industries' problems. It has already enabled new formulations for drugs-for example, the FDA-approved Abraxane from American Pharmaceuticals, which has indications for the treatment of metastable breast cancers. Other drugs that are in the R&D pipeline or in regulatory approval stage are those developed by NanoHorizons for the treatment of skin disorders and infections. In the future, nanotechnology will enhance the drug discovery process, through miniaturization, automation, speed and reliability of assays. Our research indicates that nano-enabled drug discovery can make important contributions to solving the problems listed above.
It can:
• Improve our understanding of chemicals at the cellular/molecular level
• Improve identification and validation of target proteins and drugs
• Increase throughput
• Reduce the time required to identify new drugs
• Reduce the amount of precious reagents required to carry out screening of potential drugs
• Improve visualization of drug interactions
This 218-page report discusses how nano-enabled discovery and validation technologies can expand the hit rate for promising compounds in the pipeline, and expedite their progress through to market. It covers labs-on-a-chip/arrays, as well as nanoparticulate and self-assembled solutions and provides an in-depth analysis of all the drivers, restraints, challenges, regulatory issues and government funding policies that impact nano-enabled drug discovery, along with profiles of the regulatory and funding environments for this kind of technology in 20 major countries. It also provides eight-year forecasts that break out the market by key applications segments and product types and also offers profiles of 30 firms already active in this space.
We believe that this report will be of vital interest to strategic planners, marketing managers and product development managers at all pharmaceutical, biotechnology, life science, test and measurement, specialty chemical, nanomaterials and biotechnology companies that may be interested in nanotechnology. This report may also benefit individuals and investors who track advances in the evolving nanotechnology market, including venture capitalists, healthcare equity analysts, academic researchers and scientific staff.
|
Content
Executive Summary
E.1 Introduction
E.2 Drivers, Restraints and Challenges Affecting the Growth of Nano-Enabled Drug Discovery
E.3 The Pharmaceutical Market, Regulatory Factors and Sources of Funding for Nanotechnology
E.4 Which Countries will Lead in Nano-Enabled Drug Discovery?
E.5 Nano-enabled Drug Discovery Technologies and Products
E.6 The Players
E.7 Market Forecast Summaries
Chapter One: Introduction
1.1 Overview
1.2 Objectives
1.3 Scope of the Report/Research Methodology and Information Sources
1.4 Plan of Report
Chapter Two: Drivers, Restraints, Challenges, Regulatory Issues and Government Funding Policies
2.1 Introduction
2.2 Drivers for the Growth of Nano-enabled Drug Discovery
2.2.1 Social and economic drivers
2.2.2 Technological Drivers
2.2.3 Increased Funding Drives Nano-enabled Drug Discovery
2.3 Factors Restricting the Market Growth of Nano-enabled Drug Discovery
2.3.1 Uncertainty
2.3.2 Public Awareness and Perception
2.3.3 Environmental Concerns
2.3.4 Detection of Incurable Diseases Could Place Immense Pressure on Pharmaceutical Companies
2.3.5 Huge Expectations May Not Be Realized
2.4 Technology Challenges
2.4.1 Nanotechnologies are Required to Meet the Demands for Drug-Discovery Applications
2.4.2 The Long-Term Stability of Nanomaterials Causes Concern
2.4.3 Technical Issues In Nano-Assembly and Molecular Manufacturing are Affecting Rapid Commercialization
2.4.4 Overcoming Barriers to Collaboration
2.4.5 Lack of Test Standardization
2.4.6 Scalability Posing a Challenge to Nanomedicine Initiatives
2.4.7 Pharmaceutical Companies May Be Reluctant to Invest In Nanotechnology
2.5 The Pharmaceutical Market, Regulatory Factors and Sources of Funding for Nanotechnology
2.5.1 United States
2.5.2 Canada
2.5.3 Europe
2.5.3.1 Belgium and the Netherlands
2.5.3.2 Denmark
2.5.3.3 Finland
2.5.3.4 Sweden
2.5.3.5 France
2.5.3.6 Germany
2.5.3.7 United Kingdom
2.5.3.8 Ireland
2.5.3.9 Switzerland
2.5.3.10 Italy
2.5.4 Japan
2.5.5 Taiwan
2.5.6 Singapore
2.5.7 South Korea
2.5.8 China
2.5.9 Australia
2.5.10 Israel
Chapter Three: Applications of Nanotechnology in Drug Discovery
3.1 A Historical Overview of the Drug Discovery Process
3.2 An Introduction to Nanotechnology in Drug Discovery and Development
3.3 Nano-enabled Drug Discovery Tools
3.3.1 Atomic Force Microscopy (AFM) and the Congruent Force Intermolecular Test
3.3.2 Field-Ion Microscope
3.3.3 Near-field Scanning Optical Microscope (SNOM or NSOM)
3.3.4 Surface Plasmon Resonance
3.3.5 Nano-Mass Spectroscopy
3.3.6 Dip-Pen Nanolithography (DPN)
3.4 Microarrays and Nanoarrays
3.5 Microfluidics and Nanofluidics
3.6 Nanoparticles for Drug Discovery
3.6.1 Quantum Dots (QDots) and Gold Nanoparticles for High-Content and Initial Drug Screening
3.6.2 Nanoshells for Raman Spectroscopy
3.6.3 Nanobarcode Particles
3.7 Nanomaterial Drugs
3.7.1 Abraxane
3.7.2 RenaZorb
3.7.3 Antimicrobial Emulsions
3.7.4 Antioxidant and Anti-HIV Fullerenes
3.8 Future Developments
Chapter Four: The Players
4.1 Introduction
4.2 3DM Inc. (PuraMatrix)
4.3 Aclara BioSciences
4.4 Advion BioSciences, Inc.
4.5 Agilent Technologies
4.6 Alnis BioSciences, Inc.
4.7 American Pharmaceutical Partners, Inc. (Abraxis Oncology)
4.8 BioCrystal, Ltd.
4.9 BioForce Nanosciences, Inc.
4.10 BioTrove, Inc.
4.11 Caliper Life Sciences
4.12 Cepheid
4.13 CombiMatrix Corporation
4.14 CrystalPlex Corporation
4.15 C Sixty
4.16 Eksigent Technologies, LLC
4.17 Evident Technologies Inc.
4.18 Fluidigm Corporation
4.19 GeneFluidics
4.20 Gyros AB
4.21 NanoBio Corporation
4.22 Nanogen
4.23 NanoHorizons Inc.
4.24 Nanosphere
4.25 Nanostream, Inc.
4.26 PharmaSeq, Inc.
4.27 Protiveris Inc.
4.28 Quantum Dot Corp.
4.29 Sequenom
4.30 Zyomyx, Inc.
Chapter Five: Eight-Year Projections of Nano-enabled Drug Discovery Revenues
5.1 A Justification for Forecasting
5.2 Forecasting Goals and Methodology
5.2.1 Size of Addressable Markets
5.3 Forecast of Nano-enabled Drug Discovery Revenues
5.3.1 Forecast of Lab-on-Chip/Array-Based Nano-enabled Drug Discovery Revenues
5.3.1.1 Competitive Structure
5.3.2 Forecast of Nanoparticle-Based Nano-enabled Drug Discovery
5.3.2.1 Competitive Structure
5.3.3 Forecast of Self-Assembly Nano-enabled Drug Discovery
5.3.3.1 Competitive Structure
Acronyms and Abbreviations Used in this Report
List of Exhibits
Exhibit E-1: Market Drivers, Restraints and Challenges Facing the Growth of Nano-Enabled Drug Discovery
Exhibit E-2: Summary of the Pharmaceutical Market Size and Nanotechnology Funding Initiatives by Geographical Demography
Exhibit E-3: Assessment and Summary on Whether (or not) a Particular Country is Likely to Emerge as a Center for Nano-Enabled Drug Discovery
Exhibit E-4: Nano-enabled Drug Discovery Product Developers and Producers
Exhibit E-5: Eight-Year Forecasts of Worldwide Nano-enabled Drug Discovery Revenues by Application ($ Millions)
Exhibit 2-1: Market drivers fuelling the growth rate of nano-enabled drug discovery
Exhibit 2-2: Technology challenges
Exhibit 2-3: National Nanotechnology Initiative (Contribution of key agencies $ Millions)
Exhibit 3-1: Drug development process during the 1950s and 1960s
Exhibit 3-2: Drug discovery process during the 1980s
Exhibit 3-3: Drug Discovery Process Today
Exhibit 3-4: Examples of bottom-up and top-down techniques in manufacturing
Exhibit 3-5: A schematic diagram illustrating how antibodies specific to individual proteins are targeted using Atomic Force Microscopy
Exhibit 3-6: Advion's ESI Chip for MS (Courtesy of Advion Bioscience)
Exhibit 3-7: (a) An image showing the expression in cells using QDots 125
Exhibit 5-1: Nano-enabled Drug Discovery Revenue Forecasts ($ Million) and Growth Rates 199
Exhibit 5-2: Nano-enabled Drug Discovery Revenue Forecasts by Market Segments
Exhibit 5-3: Lab-on-Chip (LOC)/Array-based Nano-Enabled Drug Revenue Forecasts
Exhibit 5-4: Lab-on-Chip (LOC)/Array-based Nano-enabled Drug Discovery Revenues Forecasts ($ Million) and Growth Rates by Application Area
Exhibit 5-5: Lab-on-Chip (LOC)/Array-based Technology Market Share by Product Application
Exhibit 5-6: Market Share Trends of Major Market Participants in Lab-on-Chip (LOC)/Array-based Technologies
Exhibit 5-7: Revenue Forecasts ($ Million) and Growth Rates for Nanoparticle Materials in Drug Discovery
Exhibit 5-8: Nanoparticulate Revenue Forecasts ($ Million) and Growth Rates by Drug Discovery Application Area
Exhibit 5-9: Nanoparticulate Drug Discovery Market Share by Product Application
Exhibit 5-10: Market Share Trends of Major Market Participants in Nanoparticulate Drug Discovery
Exhibit 5-11: Revenue Forecasts ($ Million) and Growth Rates for Self-Assembly in Nano-enabled Drug Discovery
Exhibit 5-12: Self Assembly Nano-enabled Drug Discovery Revenue Forecasts ($ Million) and Growth Rates by Drug Discovery Application Area 213
Exhibit 5-13: Self-Assembly Nano-enabled Drug Discovery Market Share by Product Application
Exhibit 5-14: Market Share Trends of Major Market Participants in Self Assembly Nano-enabled Drug Discovery
|
|
|
